A Phase 2 interventional study of Leu Sil 1.0mg and Leu Sil 4.0mg in Obesity, sponsored by NuSirt Biopharma. Completed at 15 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-21.
Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24).
This is a randomized, 24-week, placebo-controlled, double-blind study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. Subjects meeting all the inclusion criteria and no exclusion criteria will be randomized to one of five study arms.
The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24) receiving two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. Secondary objectives will also assess changes in absolute body weight, percentage of patients with ≥5% body weight loss, change in waist circumference, change in HbA1c, change in fasting glucose, change in blood lipids such as cholesterol, LDL, HDL, triglycerides, change in blood pressure and changes in in C-reactive protein. In addition this study will evaluate the safety and tolerability of NS-0200 and NS-0300.
Patients will have one screening visits which will determine their eligibility based on lab tests. Once qualified, patients will be randomly assigned to either one of the treatment groups or the placebo control group and monitored for a total of 24 weeks. Patients will return to the clinic each month for lab tests, and routine examinations.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's enrollment of 267 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →NuSirt Biopharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is male, or female and, if female, meets all of the following criteria:
Exclusion Criteria:
Severe renal impairment ( \< 45 mg/mL/1.73 m2) and/or patients with acute or chronic metabolic acidosis. Acidosis is defined as >25mmol/L computed without K.
Normal is 8- 16, but acidosis is >25
Use of any of the following medications in the eight weeks prior to entering screening for study participation and during the study:
Medications associated with weight changes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
Drug: Placebo
3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Drug: Leu Sil 1.0mg · Drug: Leu Sil 4.0mg
3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Drug: Leu Sil 1.0mg · Drug: Leu Met Sil 1.0mg
3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Drug: Leu Sil 1.0mg · Drug: Leu Sil 4.0mg · Drug: Leu Met Sil 4.0mg
3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Drug: Leu Sil 1.0mg · Drug: Leu Met Sil 1.0mg · Drug: Leu Met Sil 4.0mg
Leu 1100 mg + 1mg Sil BID
Also known as: NS-0300-1.0
Leu 1100 mg + 4mg Sil BID
Also known as: NS-0300-4.0
Leu 1100 mg + Met 500mg + 1mg Sil BID
Also known as: NS-0200-1.0
Leu 1100 mg + Met 500mg + 4mg Sil BID
Also known as: NS-0200-4.0
Placebo
Percentage Body Weight Change
The percentage body weight change from baseline to Day 168 was evaluated.
Time frame: Baseline to Day 168
Change in Absolute Body Weight
The change in absolute body weight from baseline to day 168 was evaluated.
Time frame: Baseline to Day 168
Change in Percentage of Patients With ≥5% Body Weight Loss
The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.
Time frame: Baseline to Day 168
Change in Waist Circumference
The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.
Time frame: Baseline to Day 168
Change in Total Cholesterol
Changes in total cholesterol was examined by standard blood chemistry.
Time frame: Baseline to Day 168
Change in HDL Cholesterol
Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.
Time frame: Baseline, Day 168
Change in LDL Cholesterol
Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.
Time frame: Baseline, 168 days
Change in Triglycerides
The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.
Time frame: Baseline, Day 168
Change in Plasma Glucose
Change in plasma glucose was examined through standard fasting blood chemistry.
Time frame: Baseline to Day 168
Change in Hemoglobin A1c (HbA1c)
Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.
Time frame: Baseline, Day 168
Change in Diastolic Blood Pressure
Diastolic blood pressure was measured by standard blood pressure monitor.
Time frame: Baseline to Day 168
Change in Systolic Blood Pressure
Change in Systolic blood pressure was assessed in patients from baseline to Day 168
Time frame: Baseline, Day 168
Change in Inflammatory Markers
hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.
Time frame: Baseline to Day 168
Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of five treatment arms in the ratio of 1:1:1:1:1(A:B:C:D:E). The randomization was stratified by a maximum of 70% female with a BMI range between 30 kg/m2 and 45 kg/m2
| Milestone | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Started | 52 | 51 | 53 | 50 | 52 |
| Completed | 42 | 40 | 42 | 37 | 41 |
| Not completed | 10 | 11 | 11 | 13 | 11 |
| Withdrew: Adverse event | 3 | 4 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 7 | 7 | 10 | 11 | 11 |
The percentage body weight change from baseline to Day 168 was evaluated.
| percentage | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Percentage Body Weight Change | 1.121 ± 3.6241 | 0.674 ± 3.2286 | -0.489 ± 3.9041 | -0.929 ± 4.5533 | -0.552 ± 2.5924 |
The change in absolute body weight from baseline to day 168 was evaluated.
| kg | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Absolute Body Weight | 1.126 ± 3.5903 | 0.678 ± 3.2502 | -0.460 ± 4.0352 | -0.870 ± 4.5445 | -0.461 ± 2.7583 |
The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.
| Participants | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Percentage of Patients With ≥5% Body Weight Loss | 2 | 1 | 6 | 7 | 3 |
The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.
| cm | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Waist Circumference | 0.043 ± 5.5591 | 0.028 ± 5.5152 | -1.060 ± 5.5564 | -1.841 ± 4.7654 | 0.637 ± 5.7908 |
Changes in total cholesterol was examined by standard blood chemistry.
| mg/dL | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Total Cholesterol | 1.0 ± 20.33 | 0.2 ± 20.96 | 1.9 ± 20.01 | -0.7 ± 16.74 | -6.6 ± 23.48 |
Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.
| mg/dL | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in HDL Cholesterol | 1.1 ± 7.43 | 0.6 ± 7.59 | 2.4 ± 6.40 | 1.8 ± 8.21 | 1.6 ± 7.72 |
Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.
| mg/dL | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in LDL Cholesterol | -5.5 ± 15.40 | -6.6 ± 16.86 | -4.2 ± 15.81 | -5.5 ± 11.77 | -11.6 ± 19.72 |
The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.
| mg/dL | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Triglycerides | 13.4 ± 45.43 | 9.7 ± 56.42 | 1.9 ± 51.93 | -4.4 ± 47.02 | 3.5 ± 52.03 |
Change in plasma glucose was examined through standard fasting blood chemistry.
| mg/dL | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Plasma Glucose | 0.4 ± 7.98 | -1.6 ± 9.35 | 0.3 ± 9.59 | 1.1 ± 12.43 | -1.7 ± 10.87 |
Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.
| percentage of glycosylated hemoglobin | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Hemoglobin A1c (HbA1c) | 0.16 ± 0.164 | 0.09 ± 0.167 | 0.11 ± 0.165 | 0.07 ± 0.198 | 0.09 ± 0.177 |
Diastolic blood pressure was measured by standard blood pressure monitor.
| mmHg | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Diastolic Blood Pressure | -1.7 ± 7.13 | 1.8 ± 9.57 | -2.6 ± 8.10 | 1.1 ± 9.16 | -3.3 ± 7.48 |
Change in Systolic blood pressure was assessed in patients from baseline to Day 168
| mmHg | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Systolic Blood Pressure | -2.0 ± 9.97 | 0.5 ± 12.21 | -2.7 ± 9.12 | 0.6 ± 9.31 | -3.5 ± 9.29 |
hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.
| mg/L | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Change in Inflammatory Markers | 0.90 ± 2.401 | 0.12 ± 3.633 | 0.35 ± 3.385 | 0.56 ± 6.624 | 0.12 ± 3.551 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/52 (0%) | 0/52 (0%) | 14/52 (26.9%) |
| Leu Sil 1.0mg | 0/51 (0%) | 2/51 (3.9%) | 19/51 (37.3%) |
| Leu Sil 4.0mg | 0/53 (0%) | 0/53 (0%) | 12/53 (22.6%) |
| Leu Met Sil 1.0mg | 0/50 (0%) | 1/50 (2%) | 21/50 (42%) |
| Leu Met Sil 4.0mg | 0/52 (0%) | 0/52 (0%) | 19/52 (36.5%) |
| Event | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/51 | 0/53 | 1/50 | 0/52 |
| Tooth abscessInfections and infestations | 0/52 | 1/51 | 0/53 | 0/50 | 0/52 |
| HypokalaemiaMetabolism and nutrition disorders | 0/52 | 1/51 | 0/53 | 0/50 | 0/52 |
| Anal CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 1/51 | 0/53 | 0/50 | 0/52 |
| Event | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg |
|---|---|---|---|---|---|
| DiarrhoeaRenal and urinary disorders | 1/52 | 2/51 | 4/53 | 21/50 | 12/52 |
| HeadacheGeneral disorders | 4/52 | 6/51 | 0/53 | 4/50 | 5/52 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 5/52 | 6/51 | 2/53 | 4/50 | 4/52 |
| NauseaGeneral disorders | 1/52 | 4/51 | 1/53 | 4/50 | 6/52 |
| NasopharyngitisGeneral disorders | 1/52 | 5/51 | 0/53 | 1/50 | 2/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/52 | 4/51 | 0/53 | 0/50 | 0/52 |
| Increased AppetiteGeneral disorders | 2/52 | 4/51 | 2/53 | 2/50 | 3/52 |
| SinusitisGeneral disorders | 1/52 | 0/51 | 0/53 | 0/50 | 4/52 |
| Abdominal PainGastrointestinal disorders | 1/52 | 0/51 | 1/53 | 3/50 | 1/52 |
| Back PainMusculoskeletal and connective tissue disorders | 0/52 | 0/51 | 1/53 | 3/50 | 1/52 |
Subjects who met the inclusion criteria, with BMI between 30kg/m2 and 45kg/m2.
| Age, Categorical(Participants) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 51 | 53 | 50 | 52 | 258 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Mean | 41.29 ± 11.30 | 40.94 ± 11.14 | 39.55 ± 11.14 | 41.36 ± 12.66 | 42.89 ± 10.70 | 41.20 ± 11.36 |
| Sex: Female, Male(Participants) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Female | 38 | 29 | 32 | 39 | 35 | 173 |
| Male | 14 | 22 | 21 | 11 | 17 | 85 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 12 | 13 | 12 | 15 | 60 |
| Not Hispanic or Latino | 44 | 39 | 40 | 38 | 37 | 198 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 9 | 13 | 11 | 11 | 53 |
| White | 40 | 42 | 39 | 37 | 40 | 198 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 0 | 2 |
| Weight (kg)(kg) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Mean | 101.67 ± 13.856 | 105.05 ± 15.568 | 107.16 ± 17.962 | 100.18 ± 16.991 | 104.50 ± 17.405 | 103.74 ± 16.49 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Mean | 35.773 ± 3.31 | 37.179 ± 4.28 | 37.9 ± 4.20 | 36.425 ± 4.13 | 37.152 ± 4.23 | 36.89 ± 4.08 |
| Waist Circumference(cm) | Placebo | Leu Sil 1.0mg | Leu Sil 4.0mg | Leu Met Sil 1.0mg | Leu Met Sil 4.0mg | Total |
|---|---|---|---|---|---|---|
| Mean | 110.40 ± 10.998 | 112.91 ± 11.466 | 116.02 ± 12.411 | 111.17 ± 13.291 | 112.93 ± 13.311 | 112.71 ± 12.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Aug 2018, 6 months.
Results were first posted in Nov 2018, 3 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 6 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NuSirt Biopharma